United Therapeutics (NASDAQ:UTHR) Price Target Raised to $414.00

United Therapeutics (NASDAQ:UTHR) had its price target increased by Wells Fargo & Company from $295.00 to $414.00 in a report published on Wednesday,Benzinga reports. The firm currently has an equal weight rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. HC Wainwright set a $400.00 target price on shares of United Therapeutics and gave the stock a “buy” rating in a research report on Thursday, July 31st. Morgan Stanley lowered their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. UBS Group lifted their price objective on shares of United Therapeutics from $385.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of United Therapeutics in a report on Thursday, August 14th. Finally, Jefferies Financial Group raised their target price on United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $429.62.

United Therapeutics Trading Up 5.3%

Shares of UTHR opened at $400.52 on Wednesday. The firm has a market cap of $18.07 billion, a PE ratio of 15.63, a price-to-earnings-growth ratio of 5.77 and a beta of 0.62. The company’s 50 day simple moving average is $307.69 and its 200-day simple moving average is $306.32. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $436.95.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business’s revenue was up 11.7% on a year-over-year basis. During the same quarter last year, the business posted $5.85 earnings per share. As a group, equities research analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity

In related news, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the sale, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christopher Causey sold 3,000 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $423.21, for a total value of $1,269,630.00. Following the sale, the director owned 4,865 shares of the company’s stock, valued at approximately $2,058,916.65. This represents a 38.14% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 118,181 shares of company stock worth $39,441,679 in the last quarter. Corporate insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in United Therapeutics in the 1st quarter valued at about $313,000. Allianz Asset Management GmbH grew its holdings in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after buying an additional 33,254 shares during the period. LPL Financial LLC grew its holdings in United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after buying an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after buying an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new stake in United Therapeutics in the 1st quarter valued at about $227,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.